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Desloratadine Therapy Improves Allergic Rhinitis Symptoms
in Latin American Children Aged 6 to 12 Years
Paolo Tassinari,1 Nelson R. Sua´rez,2 Jorge Centeno,3 Janina Vergara Vela´squez,4
He´ctor Aguirre-Mariscal,5 Sandra N. Gonza´lez Dı´az,6
Alfredo Ferna´ndez de Co´rdova Jerves,7 and the LA Desloratadine Study Group
Objective: To determine the effectiveness of desloratadine syrup in
relieving symptoms of allergic rhinitis (AR) among children in Latin
America.
Methods: In an open-label trial conducted in 5 Latin American
countries, 455 children aged 6 to 12 years with seasonal or perennial
AR were treated with desloratadine syrup 2.5 mg/d for 6 weeks.
Thirty percent of subjects were concomitantly taking corticosteroids,
and 21.3% had a history of asthma. Efficacy was measured by
improvement in the Total Symptom Severity 4 questionnaire and
decrease in severity of individual nasal symptoms of congestion,
rhinorrhea, pruritus, and sneezing. Physicians and subjects’ caregiv-
ers rated symptom improvement in a separate assessment at final
visit.
Results: Treatment with desloratadine led to a significant decrease
in mean Total Symptom Severity 4 score, from 7.54 at baseline to
1.96 at study end (P  0.0001), and in individual symptom scores,
including congestion (P  0.0001 for all). Similar improvements
were found in groups receiving desloratadine monotherapy and
desloratadine plus corticosteroids. Allergic rhinitis symptoms were
rated “better” or “much better” by 94% of caregivers. Incidence of
adverse events was 6%.
Conclusions: Desloratadine, with or without concomitant cortico-
steroids, was efficacious and safe in the treatment of AR in this
group of Latin American children.
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Allergic rhinitis (AR) symptoms can reduce children’sperformance in school, and certain medications used to
treat AR can exacerbate this problem.1–2 Fatigue, cognitive
impairment, irritability, inattentiveness, difficulty concentrat-
ing, behavioral problems, poor test performance, and absen-
teeism are among the causes of poor school performance.3–5
A recent study of adolescents in the United Kingdom found
that students who had AR were 40% more likely to drop a
grade in their school examinations between winter and sum-
mer than healthy students,6 and Sundberg et al7 noted that
severe nasal symptoms were associated with lower grades in
Swedish adolescents. The American Academy of Allergy,
Asthma & Immunology has estimated that children in the
United States lose 2 million school days a year as a result of
AR.8
The guidelines issued by the Allergic Rhinitis and its
Impact on Asthma Workshop Group do not recommend the
use of first-generation sedating antihistamines—such as di-
phenhydramine, chlorpheniramine, and brompheniramine—
for the treatment of AR because, in part, of their marked
sedative effects.9 The US Food and Drug Administration
Nonprescription Drugs Advisory Committee recently recom-
mended that over-the-counter cold and cough medications,
some of which contain first-generation antihistamines, not be
used in children aged 2 to 5 years. In a review of its records,
the US Food and Drug Administration found 69 reports of
deaths associated with antihistamine medicines containing
diphenhydramine, chlorpheniramine, or brompheniramine.10
Nonsedating second-generation antihistamines are rec-
ommended for use in adults and adolescents.9,11 The Allergic
Rhinitis and its Impact on Asthma Workshop Group and the
European Academy of Allergology and Clinical Immunology
guidelines for pediatric patients are generally similar to those
for older patients, but they are less specific when discussing
the treatment of children.9,11,12 The American Academy of
Allergy, Asthma & Immunology guidelines recommend oral
antihistamines as a first-line therapy for children with AR.13
In controlled clinical trials, second-generation antihis-
tamines have significantly reduced nasal congestion in sub-
jects 12 years or older.14–17 Nasal congestion is often the only
presenting symptom of AR in children. Desloratadine, a
nonsedating second-generation antihistamine, has demon-
strated efficacy for the treatment of AR symptoms in adults
and adolescents,15,18,19 and results of an uncontrolled efficacy
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trial suggest that it is effective in children aged 6 to 12
years.20 Randomized, double-blind, placebo-controlled safety
studies have shown that desloratadine is safe and well toler-
ated in children as young as 6 months.21–24
Although the prevalence of pediatric AR in Latin
America has not been extensively studied, AR may affect
40% or more children in the United States by the age of 6
years.25,26 Data drawn from patient questionnaires and phy-
sician examinations in North America and western Europe
suggest that seasonal AR affects 15% to 22% of adolescents.
In some studies, perennial AR is estimated to affect only
about 1% to 8%.9 In Latin American study centers (defined as
a city or a specified geographic area) participating in the
International Study of Asthma and Allergies in Childhood,
the percentage of children who reported AR symptoms during
the previous 12 months ranged from 21% in Panama to 42%
in Argentina among 6- to 7-year olds, and from 16% in Chile
to 67% in Paraguay among 13- to 14-year olds.27 A trial
conducted in 13- to 14-year olds in Brazil during 2002 found
that 29% were current AR sufferers, and that the monthly
prevalence of AR peaked during the winter months of June,
July, and August.9
Because the frequency of AR varies widely among
countries primarily because of environmental factors, deter-
mining patient response to medications in different geo-
graphic areas is important.9 The purpose of this study was to
determine the effectiveness of desloratadine in providing




An open-label, observational, multicenter study was
conducted in pediatric subjects from approximately 100
health care centers in Mexico, Peru, Venezuela, Ecuador, and
Panama from October 1, 2004, through November 30, 2005.
Subjects aged 6 to 12 years who had a physician-confirmed
diagnosis of either seasonal or perennial AR were included.
The individual diagnosis, initiation of treatment, and the
necessary monitoring and follow-up visits depended on the
underlying medical condition and the treatment prescribed,
according to the physician’s routine practice. If the subject or
his/her guardian agreed to participate in the study, treatment
with desloratadine was initiated, and clinical data were pro-
spectively collected.
At the enrollment (baseline) visit, investigators col-
lected demographic data, including a personal and/or family
history of other atopic/allergic conditions and a list of AR
triggers; the severity of nasal AR symptoms was determined
using a questionnaire. Eligible subjects took desloratadine
syrup 2.5 mg/d (5 mL) for 6 weeks after the baseline visit.
Concomitant corticosteroid therapy (inhaled, oral, or intrana-
sal) was permitted on an as-needed basis during the study
period.
Subjects returned for a second (final) study visit at the
end of the treatment period. The use of all concomitant
medications, including corticosteroids, was documented at
this visit, and efficacy assessments were made. Any adverse
events (AEs), regardless of whether they were related to
study medication, were recorded at this time as well.
Study protocol and informed consent forms were ap-
proved by the institutional review board for each medical
center. The study was conducted in compliance with Good
Clinical Practice guidelines and under the principles of the
Helsinki Declaration. Reports of all serious AEs were com-
municated as soon as possible to the appropriate institutional
review board and/or reported in accordance with local laws
and regulations.
Efficacy Measures
Efficacy was measured using the Total Symptom
Severity (TSS4) questionnaire (Figure 1), which rates the
severity of nasal congestion, rhinorrhea, nasal pruritus, and
sneezing using a 4-point scale: 0, absent (no signs or
symptoms evident); 1, mild (signs and symptoms present,
but minimal awareness and easily tolerated); 2, moderate
(signs and symptoms definitely present and bothersome,
but tolerable); and 3, severe (signs and symptoms hard to
tolerate and may cause interference with activities of daily
living or sleeping). The questionnaire was completed by
the investigators at the baseline and final visits. Scores
from the 2 assessments of the 4 symptoms were added to
obtain the total TSS4 score. The TSS4 scores recorded at
the baseline and final visits were compared using a paired
t test.
At the final visit, subjects, caregivers, and physicians
separately rated improvements from baseline in nasal symp-
toms. Subjects were asked to rate their perception of symp-
tomatic improvement as none, mild, better, or much better,
and physicians rated each subject’s symptoms as worse, no
change, or better after treatment.
RESULTS
Demographics
The study included 455 children aged 6 to 12 years
(mean age, 8.36  2.02 years) with either seasonal or peren-
nial AR. Subjects were residents of Mexico (29.1%, n 
132), Peru (24.2%, n  110), Venezuela (22.7%, n  103),
Ecuador (13.7%, n  62), or Panama (10.3%, n  48). The
contribution of subjects to the sample size was prespecified
based on the capacity or resources of the medical centers of
each participating country. Sixty-two percent (n  282) of
subjects were boys.
Perennial AR was observed in 61% of subjects (n 
277), seasonal AR in 30% (n  138), and both in 0.2% (n
1). Thirty-nine subjects did not state which type of AR they
had. Most subjects experienced frequent AR symptoms: 45%
(n  204) reported that these symptoms affected them daily,
and 23% (n  105) were affected 3 to 5 days a week.
Ninety-two percent (n 417) of subjects reported triggers for
their AR. House dust, pet dander, and pollen, either alone or
in combination, were the most frequently cited allergens,
reported by 80% (n  334), 24% (n  101), and 19% (n 
79) of subjects, respectively. Ninety-nine percent of subjects
(n  447) had congestion, and 96% (n  436) had sneezing.
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Nearly 10% of subjects (n  45) reported concomi-
tant eczema, and 21.3% (n  97) reported concomitant
asthma (Table 1). Eighty-six percent of subjects (n  393)
had a family history of AR (42.2%, n  192), asthma
(11.0%, n  50), eczema (3.7%, n  17), or a combination
(29.5%, n  134) (Table 2). Thirty percent (n  136) of
subjects took concomitant inhaled, oral, or intranasal cor-
ticosteroids.
Most subjects (95%) returned for follow-up between 28
and 77 days. At baseline, slightly more than half of subjects
FIGURE 1. The Total Symptom Severity 4 questionnaire.




Eczema and asthma 24 5.3
Other* 29 6.4
Asthma and other 12 2.6
Eczema, asthma, and other 3 0.7
Total with history 210 46.2
No history 245 53.8
Total 455 100.0
*Urticaria, conjunctivitis, adenoiditis, pharyngitis, sinusitis, other inflammatory
processes, or unspecified.




Allergic rhinitis 192 42.2
Eczema and asthma 7 1.5
Eczema and rhinitis 25 5.5
Asthma and rhinitis 79 17.4
Eczema, asthma, and rhinitis 23 5.1
Total with history 393 86.4
No history 62 13.6
Total 455 100.0
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rated sneezing, nasal itching, congestion, and rhinorrhea as
moderate or severe (Figure 2).
Efficacy
For all subjects, the TSS4 score decreased significantly
from a mean of 7.54 at baseline to 1.96 at the final visit (P 
0.0001). Significant reductions were observed in TSS4 scores
from baseline in subjects taking desloratadine monotherapy
(from 7.58 to 2.04, P  0.0001) or desloratadine with
concomitant corticosteroids (from 7.44 to 1.79, P  0.0001)
(Figure 3). Subjects treated with desloratadine monotherapy
had a reduction in mean nasal congestion scores from 2.14 to
0.66 (P  0.0001), which was comparable to the reduction
seen in subjects treated with desloratadine plus corticoste-
roids (from 2.13 to 0.63, P  0.0001). Decreases in the other
individual symptom scores were also significant (P 
0.0001) for all subjects (Figure 4).
After desloratadine therapy, 94% (n  421) of caregiv-
ers rated the subjects’ overall symptoms as “better” or “much
better” (Figure 5). Physicians gave ratings of “better” for
overall symptoms in 79% (n  337) of subjects, for sneezing
in 86% (n  388), for nasal pruritus in 87% (n  393), for
congestion in 89% (n 403), and for rhinorrhea in 89% (n
404).
Safety
Six percent of subjects (n  25) reported a total of 33
AEs, the most frequent being headache (7/33; 21%). None of
the AEs were serious. Most AEs with an identifiable cause
were caused by coexisting disease (n  13), and AEs were
considered likely related to study medication in only 4 sub-
jects. Five subjects discontinued the study because of AEs:
epistaxis (n  2), headache/drowsiness (n  1), gastric
intolerance (n  1), or rash with pruritus (n  1).
DISCUSSION
Worldwide studies indicate that although AR is com-
mon in young schoolchildren, the prevalence is greater in
some geographic regions, such as South America and coun-
tries on the Pacific Rim.9,27,28 A study of Brazilian adoles-
cents found that prevalence of diagnosed AR increased by
37% from 1996 to 2002,28 a rise that is consistent with
previous reports in other countries.9,29,30
Allergic rhinitis symptoms can impair a child’s
school performance and affect behavior influenced by
sleep disruption. Some of these impairments may be re-
lated to nasal congestion, which both adults and children
consider the most bothersome symptom of AR.31 In a large
survey of adults in the United States (N  2355) who had
AR or cared for a child with AR, 61% of caregivers
reported that nasal congestion caused by AR affected their
child’s performance at school; the most common effects
were poor productivity or inability to concentrate.31 The
same survey reported that nasal congestion caused night-
time awakening and difficulty falling asleep in nearly 50%
of children. Another large survey (N  4927) found that
adults who consistently experienced nighttime congestion
related to AR were twice as likely to report habitual
snoring, chronic excessive daytime sleepiness, and non-
restorative sleep.32 Therefore, medications used to treat
AR should be nonsedating and not cause additional cog-
nitive impairments.
In the present study conducted in 5 Latin American
countries, most of the children enrolled (61%) had perennial
AR. Subjects identified house dust and pet dander as the most
frequent triggers of their symptoms, and 21% had a history of
asthma. Indoor allergens also exacerbate asthma, and this
result underscores the need for a comprehensive therapeutic
strategy that includes environmental control measures in
addition to an effective therapeutic agent.
FIGURE 2. Percentage of children with moderate or severe symptoms of AR at baseline.
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The results of this study indicate that desloratadine is
an efficacious and safe treatment choice for Latin Ameri-
can children with perennial or seasonal AR. Desloratadine
therapy significantly reduced nasal congestion in all sub-
jects (P  0.0001); similar decreases were noted for
rhinorrhea, nasal pruritus, and sneezing. Nearly all of the
caregivers rated symptoms of AR as “better” or “much
better” at the end of treatment. The response in the overall
patient population and groups treated with desloratadine
alone or desloratadine plus corticosteroids was comparable
(P  0.0001 for all groups), indicating that concomitant
corticosteroid therapy did not have an additional therapeu-
tic or detrimental effect on AR symptoms.
Good tolerability in a pediatric population predomi-
nantly affected by perennial AR is important because unlike
seasonal AR, which can be treated with a short course of
FIGURE 3. The TSS4 scores at baseline and after 6 weeks of desloratadine therapy in all subjects and according to the use
of concomitant corticosteroid therapy.
FIGURE 4. Changes in individual symptom scores in all subjects and according to the use of concomitant corticosteroid
therapy.
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therapy during the pollen season, perennial AR generally
requires long-term treatment.10 Subjects in this trial reported
a low incidence of all AEs (6%), and desloratadine was safe
and well tolerated.
The objective of this study was to evaluate improve-
ment in only the symptoms of AR. For this reason, the
conclusion—that there is no difference in outcome whether
desloratadine is used alone or with intranasal corticoste-
roids—should be considered with some caution. Additional
studies are needed before deciding that Latin American chil-
dren with AR can be treated as effectively with desloratadine
monotherapy as with combination therapy.
The results of this open-label, observational, multi-
center study show that symptoms of AR, including nasal
congestion, were improved with desloratadine therapy in this
group of pediatric subjects. Desloratadine is an efficacious
and safe choice for physicians in Latin America to prescribe
for children with perennial or seasonal AR.
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